AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
Log in

ASX:ACRAcrux Stock Price, Forecast & News

A$0.14
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.14
Now: A$0.14
A$0.14
50-Day Range
A$0.11
MA: A$0.13
A$0.15
52-Week Range
A$0.11
Now: A$0.14
A$0.25
Volume4,000 shs
Average Volume188,859 shs
Market Capitalization$22.74 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Acrux Limited, together with its subsidiaries, develops and commercializes specialty and generic topical pharmaceuticals in Australia, Switzerland, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was founded in 1998 and is based in West Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-3-83790100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.39 million
Cash FlowA$0.09 per share
Book ValueA$0.09 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$22.74 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ACR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACR and its competitors with MarketBeat's FREE daily newsletter.

Acrux (ASX:ACR) Frequently Asked Questions

How has Acrux's stock been impacted by COVID-19 (Coronavirus)?

Acrux's stock was trading at A$0.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACR shares have increased by 3.8% and is now trading at A$0.14. View which stocks have been most impacted by Coronavirus.

How were Acrux's earnings last quarter?

Acrux Limited (ASX:ACR) issued its quarterly earnings results on Thursday, February, 21st. The company reported ($0.02) earnings per share (EPS) for the quarter. View Acrux's earnings history.

Has Acrux been receiving favorable news coverage?

Media stories about ACR stock have been trending somewhat negative on Thursday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Acrux earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAcrux.

Who are some of Acrux's key competitors?

What other stocks do shareholders of Acrux own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acrux investors own include Australia and New Zealand Banking Group (ANZ), Lynas (LYC), Altium (ALU), Atlas Iron (AGO), Hugo Boss (BOSS), BHP Group (BHP), Beacon Roofing Supply (BECN), Billabong (BBG), Abraxas Petroleum (AXAS) and Ausdrill (ASL).

Who are Acrux's key executives?

Acrux's management team includes the following people:
  • Mr. Michael Kotsanis B.Sc., BSc, GradDipBus, MBus, CEO, MD & Exec. Director (Age 53)
  • Mr. Tim Bateman, CFO & Company Sec.
  • Ms. Felicia Colagrande BSc (Hons), MBA, Product Devel. & Technical Affairs Director
  • Mr. Charles O'Sullivan B. Pharm, Grad. Dip. Epi. & Biostats, Portfolio Director

What is Acrux's stock symbol?

Acrux trades on the ASX under the ticker symbol "ACR."

What is Acrux's stock price today?

One share of ACR stock can currently be purchased for approximately A$0.14.

How big of a company is Acrux?

Acrux has a market capitalization of $22.74 million and generates $3.39 million in revenue each year.

What is Acrux's official website?

The official website for Acrux is www.acrux.com.au.

How can I contact Acrux?

Acrux's mailing address is 103-113 Stanley St, MELBOURNE, VIC 3003, Australia. The company can be reached via phone at +61-3-83790100.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.